In silico predictions indicated that a metastatic suppressor gene such as KLF17 [35] and two cellular protein, RBM10 and TOX3 which are involved in proliferation and apoptosis of cancer cells [36], [37] could be the actors influencing the outcome of BRAF inhibitor therapy. This evidence concerns the gene BRAF and cancer.